Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...

Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025SAN MATEO, Calif., Jan. 23, 2025 (GLOBE ...

The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.

Vincerx Pharma (VINC) announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which ...

Vincerx Pharma, Inc. (NASDAQ:VINC), a pharmaceutical company, announced today an agreement with H.C. Wainwright & Co., LLC to sell up to $30 million of its common stock in an at-the-market equity ...

EST Vincerx Pharma (VINC) files $100M mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...

Vincerx Pharma, Inc. has announced a proposed merger with Oqory, Inc., a clinical-stage company developing antibody-drug conjugates (ADCs) for various cancer types. After the merger, Oqory's ...

Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. The biotech company said that it would also implement cost-cutting ...

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new ...